FibroGen Ev To Operating Cash Flow from 2010 to 2024

FGEN Stock  USD 0.36  0  1.36%   
FibroGen EV To Operating Cash Flow yearly trend continues to be very stable with very little volatility. EV To Operating Cash Flow is likely to drop to -0.48. EV To Operating Cash Flow is a valuation metric comparing FibroGen's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows. View All Fundamentals
 
EV To Operating Cash Flow  
First Reported
2010-12-31
Previous Quarter
(0.45)
Current Value
(0.48)
Quarterly Volatility
101.16979715
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check FibroGen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among FibroGen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.2 M, Interest Expense of 16.3 M or Selling General Administrative of 82.7 M, as well as many indicators such as Price To Sales Ratio of 0.55, Dividend Yield of 0.0209 or Days Sales Outstanding of 54.75. FibroGen financial statements analysis is a perfect complement when working with FibroGen Valuation or Volatility modules.
  
Check out the analysis of FibroGen Correlation against competitors.
To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.

Latest FibroGen's Ev To Operating Cash Flow Growth Pattern

Below is the plot of the Ev To Operating Cash Flow of FibroGen over the last few years. It is a valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows. FibroGen's EV To Operating Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in FibroGen's overall financial position and show how it may be relating to other accounts over time.
Ev To Operating Cash Flow10 Years Trend
Slightly volatile
   Ev To Operating Cash Flow   
       Timeline  

FibroGen Ev To Operating Cash Flow Regression Statistics

Arithmetic Mean(38.42)
Coefficient Of Variation(263.30)
Mean Deviation73.81
Median(14.97)
Standard Deviation101.17
Sample Variance10,235
Range373
R-Value0.50
Mean Square Error8,305
R-Squared0.25
Significance0.06
Slope11.23
Total Sum of Squares143,295

FibroGen Ev To Operating Cash Flow History

2024 -0.48
2023 -0.45
2022 -9.82
2021 -14.97
2020 32.99
2019 -46.26
2018 -51.2

About FibroGen Financial Statements

FibroGen investors utilize fundamental indicators, such as Ev To Operating Cash Flow, to predict how FibroGen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
EV To Operating Cash Flow(0.45)(0.48)

Pair Trading with FibroGen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if FibroGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in FibroGen will appreciate offsetting losses from the drop in the long position's value.

Moving against FibroGen Stock

  0.53GNFT GenfitPairCorr
  0.35FLGC Flora Growth CorpPairCorr
  0.35GILD Gilead SciencesPairCorr
The ability to find closely correlated positions to FibroGen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace FibroGen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back FibroGen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling FibroGen to buy it.
The correlation of FibroGen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as FibroGen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if FibroGen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for FibroGen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether FibroGen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of FibroGen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fibrogen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fibrogen Stock:
Check out the analysis of FibroGen Correlation against competitors.
To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.536
Earnings Share
(1.23)
Revenue Per Share
1.758
Quarterly Revenue Growth
0.143
Return On Assets
(0.27)
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.